GBM
MCID: GLB015
MIFTS: 75

Glioblastoma Multiforme (GBM)

Categories: Bone diseases, Cancer diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Glioblastoma Multiforme

MalaCards integrated aliases for Glioblastoma Multiforme:

Name: Glioblastoma Multiforme 12 74 52 58 54 6 15 17 71
Glioblastoma 52 58 29 54 6 43 71
Gbm 12 58
Grade Iv Adult Astrocytic Tumor 12
Primary Glioblastoma Multiforme 12
Adult Glioblastoma Multiforme 12
Spongioblastoma Multiforme 12
Primary Glioblastoma 71
Adult Glioblastoma 71

Characteristics:

Orphanet epidemiological data:

58
glioblastoma
Inheritance: Multigenic/multifactorial,Not applicable; Prevalence: 1-9/100000 (Worldwide),1-9/100000 (Europe),1-9/100000 (United States); Age of onset: All ages; Age of death: adult;

Classifications:

Orphanet: 58  
Rare neurological diseases


External Ids:

Disease Ontology 12 DOID:3068
MeSH 43 D005909
SNOMED-CT 67 63634009
MESH via Orphanet 44 D005909
ICD10 via Orphanet 33 C71.9
UMLS via Orphanet 72 C0017636 C1621958
Orphanet 58 ORPHA360
UMLS 71 C0017636 C0278878 C1514422 more

Summaries for Glioblastoma Multiforme

NIH Rare Diseases : 52 Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Signs and symptoms, such as headache, nausea, vomiting and/or drowsiness, may develop when the tumor begins to put excess pressure on the brain. Affected people may also experience other features depending on the size and location of the tumor. In most cases, the exact underlying cause is unknown; however, they can rarely occur in people with certain genetic syndromes such as neurofibromatosis type 1 , Turcot syndrome and Li Fraumeni syndrome . There is currently no cure for glioblastoma. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy .

MalaCards based summary : Glioblastoma Multiforme, also known as glioblastoma, is related to glioma susceptibility 1 and giant cell glioblastoma, and has symptoms including seizures and headache. An important gene associated with Glioblastoma Multiforme is EGFR (Epidermal Growth Factor Receptor), and among its related pathways/superpathways are TGF-Beta Pathway and Class I MHC mediated antigen processing and presentation. The drugs Trametinib and Dabrafenib have been mentioned in the context of this disorder. Affiliated tissues include brain, t cells and endothelial, and related phenotypes are seizures and muscle weakness

Disease Ontology : 12 An astrocytoma characterized by the presence of small areas of necrotizing tissue that is surrounded by anaplastic cells as well as the presence of hyperplastic blood vessels, and that has material basis in abnormally proliferating cells derives from multiple cell types including astrocytes and oligondroctyes.

Wikipedia : 74 Glioblastoma, also known as glioblastoma multiforme (GBM), is the most aggressive cancer that begins... more...

Related Diseases for Glioblastoma Multiforme

Diseases related to Glioblastoma Multiforme via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1064)
# Related Disease Score Top Affiliating Genes
1 glioma susceptibility 1 34.8 TP53 PTEN PMS2 PIK3CA NRAS MTOR
2 giant cell glioblastoma 34.5 TP53 PTEN IDH1 FGFR1 EGFR BRAF
3 glial tumor 34.3 PTEN IDH1
4 glioma 34.3 TP53 PTEN PIK3CA MIR221 MIR210 MIR21
5 mismatch repair cancer syndrome 33.8 PTEN PMS2 MSH2
6 brain cancer 33.1 TP53 PTEN PMS2 PIK3CA NRAS MSH2
7 grade iii astrocytoma 32.9 TP53 PTEN IDH1 EGFR
8 meningioma, familial 32.6 TP53 PTEN IDH1 EGFR
9 gliosarcoma 32.5 TP53 PTEN IDH1 FGFR1 EGFR
10 medulloblastoma 32.4 TP53 PTEN PIK3CA NRAS MTOR MSH2
11 neuroblastoma 32.3 TP53 PTEN PIK3CA NRAS MTOR MSH2
12 neurofibromatosis, type iv, of riccardi 32.2 TP53 PTEN MTOR HRAS
13 gliomatosis cerebri 32.2 TP53 PTEN IDH1 EGFR BRAF
14 lung cancer susceptibility 3 32.2 TP53 PTEN PIK3CA NRAS MTOR MIR21
15 oligodendroglioma 32.2 TP53 PTEN PMS2 MSH2 IDH1 FGFR1
16 adenocarcinoma 32.2 TP53 PTEN PIK3CA MSH2 HRAS FGFR1
17 fibrillary astrocytoma 32.1 TP53 PTEN IDH1 EGFR
18 exanthem 32.1 MTOR HRAS EGFR
19 pleomorphic xanthoastrocytoma 32.0 TP53 IDH1 BRAF
20 mixed glioma 32.0 TP53 PTEN IDH1 EGFR
21 adenoma 31.9 TP53 PIK3CA MSH2 BRAF
22 brain glioma 31.9 TP53 IDH1 EGFR
23 myeloma, multiple 31.9 TP53 PTEN NRAS MTOR MIR21 MIR155
24 thyroid carcinoma 31.9 TP53 PTEN PIK3CA NRAS HRAS BRAF
25 lymphoma 31.9 TP53 PMS2 PIK3CA NRAS MSH2 FGFR1
26 sarcoma 31.9 TP53 PIK3CA NRAS MTOR MSH2 HRAS
27 gastric adenocarcinoma 31.8 TP53 PTEN PIK3CA NRAS MTOR HRAS
28 tuberous sclerosis 31.8 TP53 PTEN PIK3CA MTOR
29 basal cell carcinoma 31.7 TP53 PTEN MTOR MSH2 EGFR
30 squamous cell carcinoma 31.7 TP53 PTEN PIK3CA HRAS EGFR BRAF
31 gemistocytic astrocytoma 31.7 TP53 PTEN IDH1
32 thyroid gland cancer 31.7 TP53 PTEN PIK3CA NRAS MIR221 MIR21
33 brain stem glioma 31.7 TP53 PTEN PIK3CA IDH1 FGFR1 EGFR
34 bladder cancer 31.7 TP53 PTEN PIK3CA NRAS MIR221 MIR21
35 li-fraumeni syndrome 31.6 TP53 PTEN PMS2 MSH2 IDH1 HRAS
36 rhabdomyosarcoma 31.6 TP53 PTEN PMS2 MTOR MSH2 HRAS
37 colon adenocarcinoma 31.6 TP53 PTEN PMS2 PIK3CA MIR21 EGFR
38 cholangiocarcinoma 31.6 TP53 PTEN PIK3CA MTOR MIR21 IDH1
39 leukemia, chronic myeloid 31.6 TP53 PTEN NRAS MIR155 HRAS FGFR1
40 small cell cancer of the lung 31.6 TP53 PTEN PIK3CA MIR21 EGFR
41 leukemia, chronic lymphocytic 31.6 TP53 PTEN NRAS MIR221 MIR21 MIR155
42 retinitis pigmentosa 11 31.6 TP53 PTEN HRAS EGFR
43 small cell carcinoma 31.5 TP53 PTEN EGFR
44 lynch syndrome 31.5 TP53 PTEN PMS2 PIK3CA NRAS MSH2
45 hemangioma 31.5 TP53 PTEN MTOR IDH1
46 skin carcinoma 31.5 TP53 NRAS MSH2 MIR21 MIR149 HRAS
47 high-grade astrocytoma 31.5 PTEN IDH1
48 spitz nevus 31.5 TP53 HRAS BRAF
49 prostate cancer 31.5 TP53 PTEN PIK3CA MTOR MSH2 MIR221
50 supratentorial cancer 31.5 TP53 IDH1 EGFR

Graphical network of the top 20 diseases related to Glioblastoma Multiforme:



Diseases related to Glioblastoma Multiforme

Symptoms & Phenotypes for Glioblastoma Multiforme

Human phenotypes related to Glioblastoma Multiforme:

58 (show all 15)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 seizures 58 Occasional (29-5%)
2 muscle weakness 58 Frequent (79-30%)
3 fatigue 58 Frequent (79-30%)
4 memory impairment 58 Occasional (29-5%)
5 abnormality of the cerebral white matter 58 Frequent (79-30%)
6 visual loss 58 Frequent (79-30%)
7 paralysis 58 Frequent (79-30%)
8 headache 58 Frequent (79-30%)
9 cerebral edema 58 Frequent (79-30%)
10 language impairment 58 Frequent (79-30%)
11 abnormality of nervous system physiology 58 Frequent (79-30%)
12 abnormal cell morphology 58 Very frequent (99-80%)
13 abnormal corpus callosum morphology 58 Frequent (79-30%)
14 mood changes 58 Frequent (79-30%)
15 glioblastoma 58 Obligate (100%)

UMLS symptoms related to Glioblastoma Multiforme:


seizures, headache

GenomeRNAi Phenotypes related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

26 (show all 16)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00055-A-2 10.56 EGFR HRAS MTOR PIK3CA BRAF
2 Decreased viability GR00221-A-1 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
3 Decreased viability GR00221-A-2 10.56 FGFR1 HRAS PIK3CA
4 Decreased viability GR00221-A-3 10.56 HRAS NRAS
5 Decreased viability GR00221-A-4 10.56 EGFR MTOR PIK3CA BRAF
6 Decreased viability GR00301-A 10.56 BRAF
7 Decreased viability GR00342-S-1 10.56 MTOR
8 Decreased viability GR00342-S-2 10.56 MTOR
9 Decreased viability GR00381-A-1 10.56 BRAF
10 Decreased viability GR00402-S-2 10.56 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
11 Decreased cell migration GR00055-A-1 9.72 BRAF EGFR HRAS MTOR PIK3CA
12 Decreased focal adhesion (FA) area, decreased FA length, decreased FA mean intensity, increased number of small and round FAs, increased FA abundance GR00210-A 9.65 EGFR HRAS MTOR NRAS PTEN
13 Decreased viability with paclitaxel GR00179-A-1 9.35 EGFR MTOR
14 Decreased viability with paclitaxel GR00179-A-2 9.35 MTOR
15 Decreased viability with paclitaxel GR00179-A-3 9.35 EGFR MTOR
16 Increased cell migration GR00055-A-3 9.02 BRAF EGFR HRAS MTOR PIK3CA

MGI Mouse Phenotypes related to Glioblastoma Multiforme:

45 (show all 11)
# Description MGI Source Accession Score Top Affiliating Genes
1 cardiovascular system MP:0005385 10.19 BCOR BRAF EGFR FGFR1 HRAS MTOR
2 immune system MP:0005387 10.15 BCOR BRAF EGFR FGFR1 IDH1 MSH2
3 hematopoietic system MP:0005397 10.14 BCOR BRAF EGFR FGFR1 IDH1 MSH2
4 digestive/alimentary MP:0005381 10.13 BRAF EGFR FGFR1 HRAS MSH2 NRAS
5 endocrine/exocrine gland MP:0005379 10.13 BRAF EGFR FGFR1 HRAS MTOR NRAS
6 embryo MP:0005380 10.11 BCOR BRAF EGFR FGFR1 MTOR NRAS
7 integument MP:0010771 9.97 BRAF EGFR FGFR1 HRAS MSH2 NRAS
8 neoplasm MP:0002006 9.91 BRAF EGFR HRAS MSH2 NRAS PIK3CA
9 no phenotypic analysis MP:0003012 9.7 EGFR FGFR1 HRAS MTOR NRAS PIK3CA
10 pigmentation MP:0001186 9.35 BRAF EGFR NRAS PTEN TP53
11 skeleton MP:0005390 9.32 BRAF EGFR FGFR1 HRAS IDH1 MTOR

Drugs & Therapeutics for Glioblastoma Multiforme

Drugs for Glioblastoma Multiforme (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 612)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Trametinib Approved Phase 4 871700-17-3 11707110
2
Dabrafenib Approved, Investigational Phase 4 1195765-45-7 44462760 44516822
3
tannic acid Approved Phase 4 1401-55-4
4
Benzocaine Approved, Investigational Phase 4 1994-09-7, 94-09-7 2337
5
Melphalan Approved Phase 2, Phase 3 148-82-3 4053 460612
6
Citalopram Approved Phase 2, Phase 3 59729-33-8 2771
7
Leflunomide Approved, Investigational Phase 3 75706-12-6 3899
8
Thiotepa Approved, Investigational Phase 3 52-24-4 5453
9
Trioxsalen Approved Phase 3 3902-71-4 5585
10
Donepezil Approved Phase 3 120014-06-4 3152
11
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
12
Streptozocin Approved, Investigational Phase 2, Phase 3 18883-66-4 29327
13
Paclitaxel Approved, Vet_approved Phase 3 33069-62-4 36314
14
Valproic acid Approved, Investigational Phase 3 99-66-1 3121
15
Copper Approved, Investigational Phase 2, Phase 3 7440-50-8 27099
16
Cisplatin Approved Phase 3 15663-27-1 84093 441203 2767
17
Etoposide Approved Phase 3 33419-42-0 36462
18
Doxorubicin Approved, Investigational Phase 3 23214-92-8 31703
19
Docetaxel Approved, Investigational Phase 3 114977-28-5 148124
20
Gemcitabine Approved Phase 3 95058-81-4 60750
21
Vincristine Approved, Investigational Phase 3 2068-78-2, 57-22-7 5978
22
chloroquine Approved, Investigational, Vet_approved Phase 3 54-05-7 2719
23
Prednisone Approved, Vet_approved Phase 3 53-03-2 5865
24
Bevacizumab Approved, Investigational Phase 3 216974-75-3
25
Iodine Approved, Investigational Phase 3 7553-56-2 807
26
Fluorouracil Approved Phase 2, Phase 3 51-21-8 3385
27
Povidone Approved Phase 3 9003-39-8
28
Povidone-iodine Approved Phase 3 25655-41-8
29
Meloxicam Approved, Vet_approved Phase 2, Phase 3 71125-38-7 5281106 54677470
30
Hydroxychloroquine Approved Phase 2, Phase 3 118-42-3 3652
31
Flucytosine Approved, Investigational Phase 2, Phase 3 2022-85-7 3366
32
Carmustine Approved, Investigational Phase 3 154-93-8 2578
33
Lomustine Approved, Investigational Phase 3 13010-47-4 3950
34
Carboplatin Approved Phase 3 41575-94-4 10339178 498142 38904
35
Histamine Approved, Investigational Phase 3 51-45-6 774
36
Dopamine Approved Phase 3 51-61-6, 62-31-7 681
37
Methylphenidate Approved, Investigational Phase 3 113-45-1 4158
38
Norepinephrine Approved Phase 3 51-41-2 439260
39
Cyproheptadine Approved Phase 3 129-03-3 2913
40
Vitamin A Approved, Nutraceutical, Vet_approved Phase 3 68-26-8, 11103-57-4, 22737-96-8 445354 9904001
41
Nimotuzumab Investigational Phase 3 780758-10-3, 828933-61-3
42
Rindopepimut Investigational Phase 3 1108208-65-6
43 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
44
Semustine Experimental, Investigational Phase 2, Phase 3 13909-09-6
45
Veliparib Investigational Phase 2, Phase 3 912444-00-9 11960529
46 Dianhydrogalactitol Investigational Phase 3 23261-20-3
47 Antiparkinson Agents Phase 2, Phase 3
48 Serine Proteinase Inhibitors Phase 3
49 Muscarinic Antagonists Phase 2, Phase 3
50 Cholinergic Antagonists Phase 2, Phase 3

Interventional clinical trials:

(show top 50) (show all 1565)
# Name Status NCT ID Phase Drugs
1 A Clinical Study of Standard TEMODAL® Regimen Versus Standard Regimen Plus Early Post-Surgery TEMODAL® Chemotherapy in Treatment on Patients With Newly Diagnosed Glioblastoma Multiforme (GBM) Completed NCT00686725 Phase 4 Temozolomide
2 Assessment of Optune Therapy for Patients With Newly Diagnosed Glioblastoma Using Advanced MRI Recruiting NCT03297125 Phase 4
3 An Open Label, Multi-center Roll-over Study to Assess Long-term Effect in Pediatric Patients Treated With Tafinlar (Dabrafenib) and/or Mekinist (Trametinib) Not yet recruiting NCT03975829 Phase 4 dabrafenib;trametinib
4 A Prospective, Non-randomized, Concurrent Control, Open Label, Post-approval Study of NovoTTF-100A in Recurrent GBM Patient Terminated NCT01756729 Phase 4
5 A Phase III Clinical Trial Evaluating DCVax®-L, Autologous Dendritic Cells Pulsed With Tumor Lysate Antigen For The Treatment Of Glioblastoma Multiforme (GBM) Unknown status NCT00045968 Phase 3 Dendritic cell immunotherapy
6 Phase II Prospective Study of Sequential Myeloablative Chemotherapy With Stem Cell Rescue for the Treatment of Selected High Risk CNS Tumors and Recurrent CNS Tumors Unknown status NCT00179803 Phase 2, Phase 3
7 Prospective Clinical Trials in the Use of Photodynamic Therapy (PDT) for the Treatment of Malignant Supratentorial Brain Tumors Unknown status NCT00003788 Phase 3 carmustine;lomustine;porfimer sodium;procarbazine hydrochloride
8 Angiotensin II Receptor Blockers, Steroids and Radiotherapy in Glioblastoma- A Randomized Multicenter Trial Unknown status NCT01805453 Phase 3 Losartan;Placebo
9 The Effect of Escitalopram on Mood, Quality of Life and Cognitive Functioning in Glioblastoma Patients Unknown status NCT02623231 Phase 2, Phase 3 Escitalopram;placebo
10 Randomized, Prospective, Multicenter Blinding Singles With Arm A and Arm B Innovative Strategy Strategy Conventional Unknown status NCT01811121 Phase 3 5-aminolévulinique acid (5-ALA);Placebo
11 PHASE I-II TRIAL OF METRONOMIC TEMOZOLAMIDE WITH INTERMITTENT INTENSIFICATION AND IRINOTECAN IN PATIENTS WITH RECURRENT GLIOBLASTOMA Unknown status NCT01308632 Phase 2, Phase 3 Temozolamide, irinotecan
12 Impact of Surgery on the Treatment of Supratentorial Malignant Gliomas in Subjects Aged 70 and Over Unknown status NCT02892708 Phase 3
13 Phase 3 Study of Carmustine Sustained Release Implant (CASANT) to Treat Newly Diagnosed Malignant Glioma Unknown status NCT01656980 Phase 3 Carmustine
14 A PHASE III TRIAL COMPARING THE USE OF RADIOSURGERY FOLLOWED BY CONVENTIONAL RADIOTHERAPY WITH BCNU TO CONVENTIONAL RADIOTHERAPY WITH BCNU FOR SUPRATENTORIAL GLIOBLASTOMA MULTIFORME Completed NCT00002545 Phase 3 carmustine
15 Randomized Study of Normal-fractionated Radiotherapy Versus Hypofractionated Radiotherapy Versus Chemotherapy in Patients Over 60 Years With Malignant Glioma Completed NCT00820963 Phase 3 temozolomide
16 Concomitant and Adjuvant Temozolomide and Radiotherapy for Newly Diagnosed Glioblastoma Multiforme - A Randomized Phase III Study Completed NCT00006353 Phase 3 temozolomide
17 A Phase III Randomized Study of SU101 Versus Procarbazine for Patients With Glioblastoma Multiforme in First Relapse Completed NCT00003293 Phase 3 leflunomide;procarbazine hydrochloride
18 A Phase III, Randomized, Open-Label Study Of IV Edotecarin Vs Temozolomide Or Carmustine (BCNU) Or Lomustine (CCNU) In Patients With Glioblastoma Multiforme At First Relapse After Alkylator-Based (NEO) Adjuvant Chemotherapy Completed NCT00068952 Phase 3 Edotecarin;Temozolomide;Carmustine (BCNU);Lomustine (CCNU)
19 A Randomized Phase III Study of Temozolomide and Short-Course Radiation Versus Short-Course Radiation Alone In The Treatment of Newly Diagnosed Glioblastoma Multiforme in Elderly Patients Completed NCT00482677 Phase 3 temozolomide
20 Phase III Study of Imatinib Mesylate in Combination With Hydroxyurea Versus Hydroxyurea Alone as an Oral Therapy in Patients With Temozolomide Resistant Progressive Glioblastoma Completed NCT00154375 Phase 3 Imatinib mesylate;Hydroxyurea
21 A Phase III Study of Radiation Therapy (RT) and O6-Benzylguanine (O6-BG) Plus BCNU Versus RT and BCNU Alone for Newly Diagnosed Glioblastoma Multiforme (GBM) and Gliosarcoma Completed NCT00017147 Phase 3 carmustine;O6-Benzylguanine
22 Randomized Phase 3 Open Label Study - Enzastaurin vs. Lomustine in Glioblastoma Completed NCT00295815 Phase 3 enzastaurin;lomustine
23 Phase-III Study of Standard Radiotherapy Plus Concomitant and Adjuvant OSAG 101 (Theraloc®) Plus Temozolomide vs. Standard Radiotherapy Plus Concomitant and Adjuvant Temozolomide in Patient With Newly Diagnosed, Histologically Confirmed Glioblastoma Multiforme Grade IV Completed NCT00753246 Phase 3 nimotuzumab
24 A Phase III Comparison of Hyperfractionated Radiation Therapy (RT) With BCNU and Conventional RT With BCNU for Supratentorial Malignant Glioma Completed NCT03722355 Phase 3 Carmustine
25 A Phase III Multicenter Study of Intratumoral/Interstitial Therapy With TransMID Compared to Best Standard of Care in Patients With Progressive and/or Recurrent, Non-Resectable Glioblastoma Multiforme Completed NCT00088400 Phase 3 TransMID
26 PRECISE - Phase III Randomized Evaluation of Convection Enhanced Delivery of IL13-PE38QQR Compared to GLIADEL® Wafer With Survival Endpoint in Glioblastoma Multiforme Patients at First Recurrence Completed NCT00076986 Phase 3 IL13-PE38QQR;prolifespan 20 with carmustine implant (GLIADEL® Wafer)
27 A Randomized Phase III Study of Short Course (One-week) Radiation Therapy Versus Standard Course (Three-week) Radiation Therapy in Elderly and/or Frail Patients With Newly Diagnosed Glioblastoma Multiforme Completed NCT01450449 Phase 3
28 A Multicenter, Open-Label, Randomized, Active-Controlled Parallel Groups Study Comparing the Efficacy and Safety of Temodal vs Semustine in the Treatment of Subjects With Recurrent Glioblastoma or Anaplastic Astrocytoma Completed NCT00335075 Phase 3 Temozolomide;Semustine
29 Chloroquine as Adjuvant to the Treatment of Glioblastoma Multiforme, A Randomized Trial Completed NCT00224978 Phase 3 Chloroquine
30 A Prospective, Multi-center Trial of NovoTTF-100A Compared to Best Standard of Care in Patients With Progressive or Recurrent GBM Completed NCT00379470 Phase 3
31 A Prospective, Multi-center Trial of NovoTTF-100A Together With Temozolomide Compared to Temozolomide Alone in Patients With Newly Diagnosed GBM. Completed NCT00916409 Phase 3 Temozolomide
32 Focal Fractionated Conformal Stereotactic Boost Following Conventional Radiotherapy of High Grade Gliomas: A Randomized Phase III Study Completed NCT00003916 Phase 3
33 A Prospective Randomised Trial Comparing Temozolomide With PCV In The Treatment Of Recurrent WHO Astrocytic Tumours Grades III And IV Completed NCT00052455 Phase 3 lomustine;procarbazine hydrochloride;temozolomide;vincristine sulfate
34 Phase III Double Blind, Placebo Controlled Study of Donepezil in the Irradiated Brain Completed NCT00369785 Phase 3 donepezil hydrochloride;Placebo
35 A Phase III Randomized Trial for the Treatment of Pediatric High Grade Gliomas at First Recurrence With a Single High Dose Chemotherapy and Autologous Stem Cell Transplant Versus Three Courses of Intermediate Dose Chemotherapy With Peripheral Blood Stem Cell (PBSC) Support Completed NCT00078988 Phase 3 carboplatin;etoposide;isotretinoin;thiotepa
36 A Randomized Phase II/III Study of Vorinostat and Local Irradiation OR Temozolomide and Local Irradiation OR Bevacizumab and Local Irradiation Followed by Maintenance Bevacizumab and Temozolomide in Children With Newly Diagnosed High-Grade Gliomas Completed NCT01236560 Phase 2, Phase 3 Temozolomide;Vorinostat
37 Phase III Trial Comparing Conventional Adjuvant Temozolomide With Dose-Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00304031 Phase 3 Concurrent temozolomide;100mg/m2 adjuvant temozolomide days 1 to 5 of 28 day cycle;75mg/m2 adjuvant temozolomide days 1-21 of 28 day cycle
38 Conventional Adjuvant Temozolomide With Dose Intensive Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT01364064 Phase 3 TMZ
39 A Phase 3, Randomized, Controlled, Double-Arm, Open-Label, Multi-center Study of VB-111 Combined With Bevacizumab vs. Bevacizumab Monotherapy in Patients With Recurrent Glioblastoma Completed NCT02511405 Phase 3 VB-111 + bevacizumab;Bevacizumab
40 Radiotherapy for Malignant Astrocytomas in the Elderly Completed NCT00430911 Phase 3 Radiotherapy
41 Multi-center, Randomized, Open-label Phase 3 Clinical Trial to Assess the Efficacy and Safety of 'INNOCELL Immuncell-LC' With Temozolomide in Newly Diagnosed Glioblastoma of Korea Completed NCT00807027 Phase 3 Activated T lymphocyte(Immuncell-LC)
42 A Phase III, Randomised, Parallel Group, Multi-Centre Study in Recurrent Glioblastoma Patients to Compare the Efficacy of Cediranib [RECENTIN™, AZD2171] Monotherapy and the Combination of Cediranib With Lomustine to the Efficacy of Lomustine Alone Completed NCT00777153 Phase 3 Cediranib;Cediranib;Lomustine Chemotherapy;Placebo Cediranib
43 An International, Randomized, Double-Blind, Controlled Study of Rindopepimut/GM-CSF With Adjuvant Temozolomide in Patients With Newly Diagnosed, Surgically Resected, EGFRvIII-positive Glioblastoma Completed NCT01480479 Phase 3 Rindopepimut (CDX-110) with GM-CSF;Temozolomide;KLH
44 Cilengitide for Subjects With Newly Diagnosed Glioblastoma and Methylated MGMT Gene Promoter - A Multicenter, Open-label, Controlled Phase III Study, Testing Cilengitide in Combination With Standard Treatment (Temozolomide With Concomitant Radiation Therapy, Followed by Temozolomide Maintenance Therapy) Versus Standard Treatment Alone (CENTRIC) Completed NCT00689221 Phase 3 Cilengitide;Temozolomide
45 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
46 Temozolomid (One Week on/One Week Off) Versus Strahlentherapie in Der Primärtherapie Anaplastischer Astrozytome Und Glioblastome Bei älteren Patienten: Eine Randomisierte Phase III-Studie (Methvsalem) Completed NCT01502241 Phase 3 Temozolomide
47 A Randomized, Double-Blind, Placebo-Controlled, Multicenter Phase III Trial of Bevacizumab, Temozolomide and Radiotherapy, Followed by Bevacizumab and Temozolomide Versus Placebo, Temozolomide and Radiotherapy Followed by Placebo and Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00943826 Phase 3 Bevacizumab;Temozolomide;Placebo
48 Phase III Trial of CCNU/Temozolomide (TMZ) Combination Therapy vs. Standard TMZ Therapy for Newly Diagnosed MGMT-methylated Glioblastoma Patients Completed NCT01149109 Phase 3 Temozolomide and lomustine;Temozolomide
49 Phase III Double-blind Placebo-Controlled Trial of Conventional Concurrent Chemoradiation and Adjuvant Temozolomide Plus Bevacizumab Versus Conventional Concurrent Chemoradiation and Adjuvant Temozolomide in Patients With Newly Diagnosed Glioblastoma Completed NCT00884741 Phase 3 Temozolomide
50 A Randomized Prospective Two Arm Clinical Trial of High Light Dose And Low Light Dose PDT in the Treatment of Recurrent Malignant Supratentorial Gliomas Using Porfimer Sodium [Photofrin] Completed NCT00118222 Phase 3 porfimer sodium

Search NIH Clinical Center for Glioblastoma Multiforme

Inferred drug relations via UMLS 71 / NDF-RT 50 :


Carmustine

Cochrane evidence based reviews: glioblastoma

Genetic Tests for Glioblastoma Multiforme

Genetic tests related to Glioblastoma Multiforme:

# Genetic test Affiliating Genes
1 Glioblastoma 29

Anatomical Context for Glioblastoma Multiforme

MalaCards organs/tissues related to Glioblastoma Multiforme:

40
Brain, T Cells, Endothelial, Breast, Lung, Testes, Spinal Cord

Publications for Glioblastoma Multiforme

Articles related to Glioblastoma Multiforme:

(show top 50) (show all 30804)
# Title Authors PMID Year
1
miR-124 and miR-137 inhibit proliferation of glioblastoma multiforme cells and induce differentiation of brain tumor stem cells. 54 61 46
18577219 2008
2
MicroRNA-21 targets LRRFIP1 and contributes to VM-26 resistance in glioblastoma multiforme. 61 46
19559015 2009
3
Up-regulation of micro-RNA-221 (miRNA-221; chr Xp11.3) and caspase-3 accompanies down-regulation of the survivin-1 homolog BIRC1 (NAIP) in glioblastoma multiforme (GBM). 61 46
18759060 2009
4
Clinical and molecular features associated with biallelic mutations in FANCD1/BRCA2. 6
16825431 2007
5
Biallelic BRCA2 mutations are associated with multiple malignancies in childhood including familial Wilms tumour. 6
15689453 2005
6
Association of biallelic BRCA2/FANCD1 mutations with spontaneous chromosomal instability and solid tumors of childhood. 6
14670928 2004
7
Recombinant single-chain variable fragment antibodies against extracellular epitopes of human multidrug resistance protein MRP3 for targeting malignant gliomas. 54 61
19937796 2010
8
Differential distribution of erbB receptors in human glioblastoma multiforme: expression of erbB3 in CD133-positive putative cancer stem cells. 54 61
20467331 2010
9
IL-6 augments the invasiveness of U87MG human glioblastoma multiforme cells via up-regulation of MMP-2 and fascin-1. 54 61
20428809 2010
10
An unusual loss of EGFR gene copy in glioblastoma multiforme in a child: a case report and analysis of a successfully derived HGG-02 cell line. 54 61
20195615 2010
11
FasL gene knock-down therapy enhances the antiglioma immune response. 54 61
20406899 2010
12
Response to erlotinib in recurrent glioblastoma multiforme showing coexpression of EGFRvIII and PTEN. 54 61
20462843 2010
13
Metabolic management of glioblastoma multiforme using standard therapy together with a restricted ketogenic diet: Case Report. 54 61
20412570 2010
14
Promising human brain tumors therapy with interference RNA intervention (iRNAi). 54 61
20118657 2010
15
XL-184, a MET, VEGFR-2 and RET kinase inhibitor for the treatment of thyroid cancer, glioblastoma multiforme and NSCLC. 54 61
20127563 2010
16
Evaluation of the prognostic value of CD44 in glioblastoma multiforme. 54 61
20150644 2010
17
TGF-beta downregulates the activating receptor NKG2D on NK cells and CD8+ T cells in glioma patients. 54 61
20150362 2010
18
O6-Methylguanine DNA methyltransferase protein expression in tumor cells predicts outcome of temozolomide therapy in glioblastoma patients. 54 61
20150365 2010
19
Cytotoxic effects of temozolomide and radiation are additive- and schedule-dependent. 54 61
19931733 2009
20
Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) and paclitaxel have cooperative in vivo effects against glioblastoma multiforme cells. 54 61
19996278 2009
21
Tumor necrosis factor-like weak inducer of apoptosis stimulation of glioma cell survival is dependent on Akt2 function. 54 61
19861406 2009
22
Plasma IGFBP-2 levels predict clinical outcomes of patients with high-grade gliomas. 54 61
19164435 2009
23
Prognostic impact of O6-methylguanine-DNA methyltransferase silencing in patients with recurrent glioblastoma multiforme who undergo surgery and carmustine wafer implantation: a prospective patient cohort. 54 61
19637364 2009
24
STAT3 is required for proliferation and maintenance of multipotency in glioblastoma stem cells. 54 61
19658181 2009
25
A novel PTEN-dependent link to ubiquitination controls FLIPS stability and TRAIL sensitivity in glioblastoma multiforme. 54 61
19808964 2009
26
Inhibition of mTOR Activates the MAPK Pathway in Glioblastoma Multiforme. 54 61
19996130 2009
27
Targeting sphingosine kinase 1 inhibits Akt signaling, induces apoptosis, and suppresses growth of human glioblastoma cells and xenografts. 54 61
19723667 2009
28
The epidermal growth factor receptor as a therapeutic target in glioblastoma multiforme and other malignant neoplasms. 54 61
19601750 2009
29
MGMT promoter hypermethylation in a series of 104 glioblastomas. 54 61
19656999 2009
30
Induction of MGMT expression is associated with temozolomide resistance in glioblastoma xenografts. 54 61
18952979 2009
31
The plasticity of oncogene addiction: implications for targeted therapies directed to receptor tyrosine kinases. 54 61
19412429 2009
32
Differential PARP cleavage: an indication for existence of multiple forms of cell death in human gliomas. 54 61
19587465 2009
33
Activation of telomerase by human cytomegalovirus. 54 61
19318640 2009
34
Evidence-based adjuvant therapy for gliomas: current concepts and newer developments. 54 61
19346643 2009
35
Tyrosine phosphorylation and CD95: a FAScinating switch. 54 61
19221505 2009
36
Evaluation of MGMT promoter methylation status and correlation with temozolomide response in orthotopic glioblastoma xenograft model. 54 61
19011762 2009
37
Radiosensitisation of U87MG brain tumours by anti-epidermal growth factor receptor monoclonal antibodies. 54 61
19293809 2009
38
Worse outcome in primary glioblastoma multiforme with concurrent epidermal growth factor receptor and p53 alteration. 54 61
19141386 2009
39
Interleukin-1 regulates the expression of sphingosine kinase 1 in glioblastoma cells. 54 61
19074142 2009
40
Significance of p53 and CD31 in astrogliomas. 54 61
18821037 2009
41
The angiopoietin 1/angiopoietin 2 balance as a prognostic marker in primary glioblastoma multiforme. 54 61
18991494 2009
42
Gene expression analysis of an EGFR indirectly related pathway identified PTEN and MMP9 as reliable diagnostic markers for human glial tumor specimens. 54 61
19657395 2009
43
Constitutive activity of JNK2 alpha2 is dependent on a unique mechanism of MAPK activation. 54 61
18940813 2008
44
Phase I/II trial of erlotinib and temozolomide with radiation therapy in the treatment of newly diagnosed glioblastoma multiforme: North Central Cancer Treatment Group Study N0177. 54 61
18955445 2008
45
The role of a single nucleotide polymorphism of MDM2 in glioblastoma multiforme. 54 61
18976073 2008
46
Epidermal growth factor receptor pathway gene expressions and biological response of glioblastoma multiforme cell lines to erlotinib. 54 61
19189656 2008
47
Anti-O6-methylguanine-methyltransferase (MGMT) immunohistochemistry in glioblastoma multiforme: observer variability and lack of association with patient survival impede its use as clinical biomarker. 54 61
18400046 2008
48
Expression of hypoxia inducible factor-1alpha in tumors of patients with glioblastoma multiforme and transitional meningioma. 54 61
18621534 2008
49
Nonsteroidal anti-inflammatory drugs suppress glioma via 15-hydroxyprostaglandin dehydrogenase. 54 61
18757412 2008
50
Interleukin-13 displaying retargeted oncolytic measles virus strains have significant activity against gliomas with improved specificity. 54 61
18665158 2008

Variations for Glioblastoma Multiforme

ClinVar genetic disease variations for Glioblastoma Multiforme:

6 (show top 50) (show all 231) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 H3-3A NM_002107.6(H3-3A):c.103G>A (p.Gly35Arg)SNV other 438766 rs1553260624 1:226252155-226252155 1:226064454-226064454
2 MED12 NM_005120.3(MED12):c.5980C>T (p.Arg1994Trp)SNV other 438772 rs1556339256 X:70357729-70357729 X:71137879-71137879
3 MSH2 NM_000251.2(MSH2):c.1958_1965del (p.Asn653fs)deletion Pathogenic 590849 rs1558518449 2:47702360-47702367 2:47475221-47475228
4 TP53 NM_000546.5(TP53):c.818G>T (p.Arg273Leu)SNV Pathogenic 376655 rs28934576 17:7577120-7577120 17:7673802-7673802
5 TP53 NM_000546.5(TP53):c.841G>T (p.Asp281Tyr)SNV Pathogenic 376585 rs764146326 17:7577097-7577097 17:7673779-7673779
6 TP53 NM_000546.5(TP53):c.841G>A (p.Asp281Asn)SNV Pathogenic 376586 rs764146326 17:7577097-7577097 17:7673779-7673779
7 TP53 NM_000546.5(TP53):c.537T>G (p.His179Gln)SNV Pathogenic 376607 rs876660821 17:7578393-7578393 17:7675075-7675075
8 IDH1 NM_005896.3(IDH1):c.395G>A (p.Arg132His)SNV Pathogenic 156444 rs121913500 2:209113112-209113112 2:208248388-208248388
9 MTOR NM_004958.4(MTOR):c.4448G>T (p.Cys1483Phe)SNV Pathogenic 190121 rs786205165 1:11217230-11217230 1:11157173-11157173
10 TP53 NM_000546.5(TP53):c.584T>C (p.Ile195Thr)SNV Pathogenic 216077 rs760043106 17:7578265-7578265 17:7674947-7674947
11 PTEN NM_000314.7(PTEN):c.697C>T (p.Arg233Ter)SNV Pathogenic 7813 rs121909219 10:89717672-89717672 10:87957915-87957915
12 PTEN NM_000314.7(PTEN):c.389G>A (p.Arg130Gln)SNV Pathogenic 7829 rs121909229 10:89692905-89692905 10:87933148-87933148
13 TP53 NM_000546.5(TP53):c.742C>T (p.Arg248Trp)SNV Pathogenic 12347 rs121912651 17:7577539-7577539 17:7674221-7674221
14 TP53 NM_000546.5(TP53):c.733G>T (p.Gly245Cys)SNV Pathogenic 12349 rs28934575 17:7577548-7577548 17:7674230-7674230
15 TP53 NM_000546.5(TP53):c.725G>A (p.Cys242Tyr)SNV Pathogenic 12354 rs121912655 17:7577556-7577556 17:7674238-7674238
16 TP53 NM_000546.5(TP53):c.743G>A (p.Arg248Gln)SNV Pathogenic 12356 rs11540652 17:7577538-7577538 17:7674220-7674220
17 TP53 NM_000546.5(TP53):c.733G>A (p.Gly245Ser)SNV Pathogenic 12365 rs28934575 17:7577548-7577548 17:7674230-7674230
18 TP53 NM_000546.5(TP53):c.818G>A (p.Arg273His)SNV Pathogenic 12366 rs28934576 17:7577120-7577120 17:7673802-7673802
19 TP53 NM_000546.5(TP53):c.659A>C (p.Tyr220Ser)SNV Pathogenic 12383 rs121912666 17:7578190-7578190 17:7674872-7674872
20 HRAS NM_005343.4(HRAS):c.34G>A (p.Gly12Ser)SNV Pathogenic 12602 rs104894229 11:534289-534289 11:534289-534289
21 HRAS NM_005343.4(HRAS):c.35G>C (p.Gly12Ala)SNV Pathogenic 12603 rs104894230 11:534288-534288 11:534288-534288
22 HRAS NM_005343.4(HRAS):c.34G>T (p.Gly12Cys)SNV Pathogenic 12613 rs104894229 11:534289-534289 11:534289-534289
23 PIK3CA NM_006218.4(PIK3CA):c.3140A>G (p.His1047Arg)SNV Pathogenic 13652 rs121913279 3:178952085-178952085 3:179234297-179234297
24 PIK3CA NM_006218.4(PIK3CA):c.3140A>T (p.His1047Leu)SNV Pathogenic 13653 rs121913279 3:178952085-178952085 3:179234297-179234297
25 PIK3CA NM_006218.4(PIK3CA):c.1634A>C (p.Glu545Ala)SNV Pathogenic 13659 rs121913274 3:178936092-178936092 3:179218304-179218304
26 NRAS NM_002524.5(NRAS):c.182A>G (p.Gln61Arg)SNV Pathogenic 13900 rs11554290 1:115256529-115256529 1:114713908-114713908
27 BRAF NM_004333.6(BRAF):c.1799T>A (p.Val600Glu)SNV Pathogenic 13961 rs113488022 7:140453136-140453136 7:140753336-140753336
28 PIK3CA NM_006218.4(PIK3CA):c.3139C>T (p.His1047Tyr)SNV Pathogenic 39705 rs121913281 3:178952084-178952084 3:179234296-179234296
29 BRAF NM_004333.6(BRAF):c.1787G>T (p.Gly596Val)SNV Pathogenic 40387 rs397507483 7:140453148-140453148 7:140753348-140753348
30 EGFR NM_005228.5(EGFR):c.2156G>C (p.Gly719Ala)SNV Pathogenic 45225 rs121913428 7:55241708-55241708 7:55174015-55174015
31 PIK3CA NM_006218.4(PIK3CA):c.1637A>G (p.Gln546Arg)SNV Pathogenic 45466 rs397517201 3:178936095-178936095 3:179218307-179218307
32 PMS2 NM_000535.7(PMS2):c.1831dup (p.Ile611fs)duplication Pathogenic 91317 rs63750250 7:6026564-6026565 7:5986933-5986934
33 TP53 NM_000546.5(TP53):c.638G>A (p.Arg213Gln)SNV Pathogenic 135359 rs587778720 17:7578211-7578211 17:7674893-7674893
34 TP53 NM_000546.5(TP53):c.844C>G (p.Arg282Gly)SNV Pathogenic 140821 rs28934574 17:7577094-7577094 17:7673776-7673776
35 TP53 NM_000546.5(TP53):c.842A>G (p.Asp281Gly)SNV Pathogenic 141141 rs587781525 17:7577096-7577096 17:7673778-7673778
36 TP53 NM_000546.5(TP53):c.659A>G (p.Tyr220Cys)SNV Pathogenic 127819 rs121912666 17:7578190-7578190 17:7674872-7674872
37 TP53 NM_000546.5(TP53):c.743G>T (p.Arg248Leu)SNV Pathogenic 230253 rs11540652 17:7577538-7577538 17:7674220-7674220
38 NRAS NM_002524.5(NRAS):c.182A>C (p.Gln61Pro)SNV Pathogenic 280409 rs11554290 1:115256529-115256529 1:114713908-114713908
39 BCOR NM_001123383.1(BCOR):c.3779_3780AG[1] (p.Leu1262fs)short repeat Pathogenic 284290 rs886042842 X:39922288-39922289 X:40063035-40063036
40 NRAS NM_002524.5(NRAS):c.183A>T (p.Gln61His)SNV Pathogenic 373003 rs121913255 1:115256528-115256528 1:114713907-114713907
41 PTEN NM_001304718.2(PTEN):c.-363C>GSNV Pathogenic 375958 rs121909224 10:89692904-89692904 10:87933147-87933147
42 PIK3CA NM_006218.4(PIK3CA):c.1357G>A (p.Glu453Lys)SNV Pathogenic 376470 rs1057519925 3:178928079-178928079 3:179210291-179210291
43 TP53 NM_000546.5(TP53):c.712T>C (p.Cys238Arg)SNV Pathogenic 376576 rs1057519981 17:7577569-7577569 17:7674251-7674251
44 TP53 NM_000546.5(TP53):c.713G>T (p.Cys238Phe)SNV Pathogenic 376574 rs730882005 17:7577568-7577568 17:7674250-7674250
45 PIK3CA NM_006218.4(PIK3CA):c.1030G>A (p.Val344Met)SNV Pathogenic/Likely pathogenic 376498 rs1057519942 3:178921548-178921548 3:179203760-179203760
46 PTEN NM_000314.7(PTEN):c.389G>T (p.Arg130Leu)SNV Pathogenic/Likely pathogenic 376509 rs121909229 10:89692905-89692905 10:87933148-87933148
47 MTOR NM_004958.4(MTOR):c.6644C>A (p.Ser2215Tyr)SNV Pathogenic/Likely pathogenic 376129 rs587777894 1:11184573-11184573 1:11124516-11124516
48 PIK3CA NM_006218.4(PIK3CA):c.1624G>C (p.Glu542Gln)SNV Pathogenic/Likely pathogenic 376244 rs121913273 3:178936082-178936082 3:179218294-179218294
49 TP53 NM_000546.5(TP53):c.818G>C (p.Arg273Pro)SNV Pathogenic/Likely pathogenic 231060 rs28934576 17:7577120-7577120 17:7673802-7673802
50 IDH1 NM_005896.3(IDH1):c.394C>G (p.Arg132Gly)SNV Pathogenic/Likely pathogenic 375892 rs121913499 2:209113113-209113113 2:208248389-208248389

Copy number variations for Glioblastoma Multiforme from CNVD:

7 (show top 50) (show all 760)
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 13315 1 1 117600000 Gain Glioblastoma multiforme
2 13333 1 1 124300000 Gain Glioblastoma multiforme
3 13339 1 1 124300000 Loss Glioblastoma multiforme
4 13340 1 1 124300000 Loss Glioblastoma multiforme
5 13341 1 1 124300000 Loss Glioblastoma multiforme
6 13359 1 1 12600000 Gain Glioblastoma multiforme
7 13365 1 1 16100000 Gain Glioblastoma multiforme
8 13750 1 1 27800000 Loss Glioblastoma multiforme
9 13761 1 1 28000000 Deletion Glioblastoma multiforme
10 13763 1 1 28000000 Gain Glioblastoma multiforme
11 13775 1 1 39600000 Loss Glioblastoma multiforme
12 13792 1 1 51300000 Loss Glioblastoma multiforme
13 13822 1 1 7200000 Deletion MTHFR Glioblastoma multiforme
14 14314 1 107000000 111600000 Gain Glioblastoma multiforme
15 14414 1 107915304 108309068 amplification VAV3 Glioblastoma multiforme
16 14609 1 109636509 109651136 Fusion MYBPHL Glioblastoma multiforme
17 15403 1 115061059 115084034 Fusion CSDE1 Glioblastoma multiforme
18 16435 1 124300000 247249719 Gain Glioblastoma multiforme
19 16436 1 124300000 247249719 Gain Glioblastoma multiforme
20 16437 1 124300000 247249719 Gain Glioblastoma multiforme
21 16444 1 124300000 247249719 Loss Glioblastoma multiforme
22 16683 1 130300000 212100000 Gain ATP2B4 Glioblastoma multiforme
23 19008 1 148161834 148166860 Copy number SF3B4 Glioblastoma multiforme
24 19791 1 151370387 155734861 Gain CLK2 Glioblastoma multiforme
25 20600 1 153272923 153289968 Fusion DCST1 Glioblastoma multiforme
26 20612 1 153300000 154800000 Gain RAB25 Glioblastoma multiforme
27 21114 1 156847119 156923130 Copy number SPTA1 Glioblastoma multiforme
28 22041 1 16450831 16482564 Copy number EPHA2 Glioblastoma multiforme
29 23682 1 172900000 185800000 Gain Glioblastoma multiforme
30 24288 1 178190530 178346919 Fusion CEP350 Glioblastoma multiforme
31 25428 1 189000000 197500000 Gain Glioblastoma multiforme
32 25567 1 191357783 191486465 Fusion CDC73 Glioblastoma multiforme
33 26137 1 197500000 205300000 Amplification LRRN5 Glioblastoma multiforme
34 26138 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
35 26139 1 197500000 205300000 Amplification MDM4 Glioblastoma multiforme
36 26142 1 197500000 205300000 Amplification NFASC Glioblastoma multiforme
37 26146 1 197500000 205300000 Amplificationlication HDMX Glioblastoma multiforme
38 26474 1 200429740 200554958 Truncation LGR6 Glioblastoma multiforme
39 26515 1 200858000 202110000 Copy number MDM4 Glioblastoma multiforme
40 26660 1 201942811 203355851 Amplification MDM4 Glioblastoma multiforme
41 28554 1 223214607 229308654 Gain ARF1 Glioblastoma multiforme
42 28555 1 223214607 229308654 Gain WNT3A Glioblastoma multiforme
43 29626 1 233890968 234060340 Fusion LYST Glioblastoma multiforme
44 30289 1 241700000 247249719 Amplification AKT3 Glioblastoma multiforme
45 30407 1 2429834 2447886 Fusion PANK4 Glioblastoma multiforme
46 31747 1 30500000 171200000 Gain Glioblastoma multiforme
47 32775 1 3928417 3978407 Deletion Glioblastoma multiforme
48 32899 1 4028404 6333694 Deletion AJAP1 Glioblastoma multiforme
49 32900 1 4028404 6333694 Deletion CHD5 Glioblastoma multiforme
50 33876 1 4952248 20897624 Deletion CDC42 Glioblastoma multiforme

Expression for Glioblastoma Multiforme

Search GEO for disease gene expression data for Glioblastoma Multiforme.

Pathways for Glioblastoma Multiforme

Pathways related to Glioblastoma Multiforme according to GeneCards Suite gene sharing:

(show top 50) (show all 106)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.62 TP53 PIK3CA NRAS MTOR HRAS FGFR1
2
Show member pathways
13.54 TP53 PTEN PIK3CA NRAS MTOR HRAS
3
Show member pathways
13.43 TP53 PIK3CA NRAS HRAS FGFR1 EGFR
4
Show member pathways
13.3 TP53 PTEN NRAS MTOR HRAS EGFR
5
Show member pathways
13.19 TP53 PIK3CA NRAS HRAS EGFR BRAF
6
Show member pathways
13.19 TP53 PTEN PIK3CA MTOR FGFR1 EGFR
7
Show member pathways
13.17 TP53 PTEN NRAS MTOR HRAS FGFR1
8
Show member pathways
13.09 TP53 PTEN PIK3CA NRAS MTOR HRAS
9
Show member pathways
13.06 TP53 PTEN PIK3CA NRAS MTOR HRAS
10
Show member pathways
13.02 TP53 PIK3CA NRAS MTOR HRAS EGFR
11
Show member pathways
13.02 PTEN PIK3CA NRAS MTOR HRAS EGFR
12
Show member pathways
12.99 PTEN PIK3CA NRAS HRAS EGFR BRAF
13
Show member pathways
12.96 PTEN PIK3CA NRAS MTOR HRAS FGFR1
14
Show member pathways
12.92 PIK3CA NRAS HRAS EGFR BRAF
15
Show member pathways
12.88 TP53 PTEN PIK3CA NRAS MTOR MSH2
16 12.87 TP53 NRAS HRAS FGFR1 EGFR BRAF
17
Show member pathways
12.85 PTEN PIK3CA MTOR HRAS BRAF
18
Show member pathways
12.84 PIK3CA NRAS HRAS FGFR1 EGFR BRAF
19 12.83 TP53 PTEN PIK3CA NRAS MTOR MSH2
20
Show member pathways
12.82 TP53 PTEN PIK3CA NRAS MTOR HRAS
21
Show member pathways
12.8 TP53 PTEN PIK3CA NRAS MTOR HRAS
22
Show member pathways
12.79 TP53 PTEN PIK3CA NRAS MTOR HRAS
23
Show member pathways
12.76 PIK3CA NRAS MTOR HRAS EGFR
24
Show member pathways
12.75 TP53 NRAS HRAS EGFR BRAF
25 12.75 PIK3CA NRAS HRAS FGFR1 EGFR BRAF
26
Show member pathways
12.73 PIK3CA NRAS MTOR HRAS EGFR
27
Show member pathways